Leukemia & Lymphoma Research

Syncona, UCLB form Autolus cancer immunotherapy company

Friday, January 23, 2015

Syncona, a London-based subsidiary of the Wellcome Trust, and UCL Business, the wholly-owned technology transfer company of University College London (UCL), have announced the creation of Autolus, a London-based biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies for hematological and solid tumors. Autolus is founded upon the work of Dr. Martin Pule, an academic clinical hematologist and thought-leader in T-cell engineering. Syncona has committed $33.5 million to Autolus in a Series A financing. Dr. Christian Itin, former CEO of Micromet, has joined the company as chairman.

[Read More]

BioInvent inks agreement with Cancer Research U.K., CRT and LLR

Wednesday, January 21, 2015

BioInvent International, a research-based pharmaceutical company based in Sweden, has reached an agreement with Cancer Research U.K.Cancer Research Technology (CRT), the charity’s development and commercialization arm, and Leukemia & Lymphoma Research (LLR) to take its investigational drug, BI-1206, into a collaborative phase I/II trial for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

[Read More]